Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Reductive Amination. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel leucine dehydrogenase mutants enable high-efficiency synthesis of unnatural amino acids with improved stability and conversion rates for scalable pharmaceutical manufacturing.
Patent CN119913221A reveals enzymatic route for ACEI intermediates. Offers high stereoselectivity and cost reduction in pharmaceutical intermediate manufacturing supply chains.
Patent CN112852771A details enzymatic synthesis of chiral amino alcohols using imine reductase, offering high stereoselectivity and mild conditions for pharmaceutical manufacturing.
Patent CN113106078B reveals novel LaLeuDH mutants enabling 1.5M substrate tolerance and coenzyme-free synthesis, offering significant cost reduction in pharmaceutical intermediate manufacturing.
Patent CN114958934A reveals a novel glutamate dehydrogenase method for L-glufosinate. Achieve high purity and cost reduction in agrochemical intermediate manufacturing.
Patent CN104263797A details a high-yield enzymatic resolution process for R-1-aminotetralin, offering significant supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN104178533B details enzymatic synthesis of R-3-aminobutanol. Offers high purity, cost efficiency, and scalable supply chain solutions for global pharmaceutical manufacturers.
Patent CN102978251A reveals a low-cost enzymatic route for L-tert-leucine. Achieve >99% optical purity and significant cost reduction in pharmaceutical intermediate manufacturing.